Update shared on 20 Nov 2025
Fair value Decreased 2.94%Narrative Update on Hyperfine: Analyst Price Target Revision
Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment.
What's in the News
- Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively. (Key Developments)
- Full year 2025 revenue is now projected at $13 to $14 million. (Key Developments)
- Hyperfine announced plans to expand the clinical use of its Swoop system into the operating room and is launching a new study to evaluate portable MRI applications in neurosurgical procedures. (Key Developments)
- The company launched PULSE, a subscription-based platform designed to advance research, development, and collaboration among portable MRI system users. (Key Developments)
- Hyperfine received UK Conformity Assessment approval for its Optive AI software, following US FDA clearance, to enhance international access and image quality for its Swoop portable MRI system. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased slightly from $1.70 to $1.65.
- Discount Rate has risen from 7.52% to 7.77%.
- Revenue Growth forecast has increased from 44.09% to 46.56%.
- Net Profit Margin has improved from 12.88% to 13.38%.
- Future P/E ratio has increased from 48.74x to 55.09x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.